Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Melanoma and Cancer Vaccines

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3335
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Melanoma and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Cancer Vaccines.

    To find out more about Triple Analysis: Leukemia, Melanoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
AC Immune
Actelion
Actinium Pharmaceuticals
Adaptimmune
Adherex
Advanced Life Sciences
Advaxis
AEgera
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Arca biopharma
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Choongwae
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Curacyte
CureTech
CureVac
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
DNAVEC
Dong-A
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
Flamel Technologies
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GlycoMimetics
Gradalis
Hanmi
Hayashibara
Heat Biologics
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karyon-CTT
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Memgen
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Momotaro-Gene
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
Oasmia
Oncalis
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protherics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Reliance Life Sciences
responsif
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Southern Research Institute
Spirogen
Stemline Therapeutics
Sunesis
SuperGen
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
WntResearch
XBiotech
Xencor
Xerion
Yamasa Corporation
York Pharma
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
ADXS11-001
AE-37
AEB071
agatolimod
AGS-003
aldesleukin
alemtuzumab
ALT-801
amonafide malate
amsacrine
ANZ-207
APO-866
ARRY-438162
astuprotimut-r
Auto TAG vaccine
AVX-701
axitinib
barasertib
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
bisantrene
BMS-663513
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
Buparlisib
BV-NSCLC-001
Cabozantinib
CB-10-01
CDX-1307
CG-201
cilengitide
cladribine
clofarabine
cositecan
CreaVax-PC
CSF-GM
CT-011
CV-9103
CV-9201
CVac
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
DCVax-prostate
decitabine
denenicokin
denileukin diftitox
dinaciclib
dovitinib lactate
E-75
E7449
elacytarabine
EMD-273063
emepepimut-S
endostatin
enocitabine
entinostat
epirubicin
everolimus
Exherin
fresolimumab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
GI-4000
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
ICT-107
idarubicin
imatinib mesilate
imMucin
IMO-2055
INCB-24360
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
LGX818
LipoVIL12
lumiliximab
MDX-1379
MetXia
MGN-1601
midostaurin
mitoxantrone
MKC-1106-MT
MORAb-004
MVA-BN Her-2 vaccine
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
peginterferon alfa-2b
pentostatin
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
RAF-265
ramucirumab
razoxane
retaspimycin
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
rituximab
S-488410
sagopilone
sargramostim
SCIB-1
selumetinib
sipuleucel-T
sobuzoxane
sunitinib malate
Survivac
talminogene laherparepvec
tamibarotene
teniposide
tesetaxel
TG-4010
thalidomide
thymalfasin
tipapkinogene sovacivec
tipifarnib
trabedersen
tremelimumab
TroVax
velimogene aliplasmid
veliparib
vemurafenib
verpasep caltespen
verubulin
vinflunine ditartrate
vitespen
volociximab
vosaroxin
VX-001
YM-155
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Cancer Vaccines.
    To find out more about Triple Analysis: Leukemia, Melanoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Melanoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides. Learn More


Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Decoding Big Pharmas R&D Strategy in Oncology
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More